Design, Synthesis, and Analysis of a Polyethelene Glycol-Modified (PEGylated) Small Molecule Inhibitor of Integrin α4β1 with Improved Pharmaceutical Properties
- 1 February 2005
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 312 (2) , 742-750
- https://doi.org/10.1124/jpet.104.075648
Abstract
Integrin α4β1 plays an important role in inflammatory processes by regulating the migration of leukocytes into inflamed tissues. Previously, we identified BIO5192 [2(S)-{[1-(3,5-dichloro-benzenesulfonyl)-pyrrolidine-2(S)-carbonyl]-amino}-4-[4-methyl-2(S)-(methyl-{2-[4-(3-o-tolyl-ureido)-phenyl]-acetyl}-amino)-pentanoylamino]-butyric acid], a highly selective and potent (KD of 9 pM) small molecule inhibitor of α4β1. Although BIO5192 is efficacious in various animal models of inflammatory disease, high doses and daily treatment of the compound are needed to achieve a therapeutic effect because of its relatively short serum half-life. To address this issue, polyethylene glycol modification (PEGylation) was used as an approach to improve systemic exposure. BIO5192 was PEGylated by a targeted approach in which derivatizable amino groups were incorporated into the molecule. Two sites were identified that could be modified, and from these, five PEGylated compounds were synthesized and characterized. One compound, 2a-PEG (KD of 19 pM), was selected for in vivo studies. The pharmacokinetic and pharmacodynamic properties of 2a-PEG were dramatically improved relative to the unmodified compound. The PEGylated compound was efficacious in a rat model of experimental autoimmune encephalomyelitis at a 30-fold lower molar dose than the parent compound and required only a once-a-week dosing regimen compared with a daily treatment for BIO5192. Compound 2a-PEG was highly selective for α4β1. These studies demonstrate the feasibility of PEGylation of α4β1-targeted small molecules with retention of activity in vitro and in vivo. 2a-PEG, and related compounds, will be valuable reagents for assessing α4β1 biology and may provide a new therapeutic approach to treatment of human inflammatory diseases.Keywords
This publication has 35 references indexed in Scilit:
- Comparative Assessment of the Ligand and Metal Ion Binding Properties of Integrins α9β1 and α4β1Biochemistry, 2002
- Crystal Structure of the Extracellular Segment of Integrin αVβ3 in Complex with an Arg-Gly-Asp LigandScience, 2002
- Evidence That Ligand and Metal Ion Binding to Integrin α4β1 Are Regulated through a Coupled EquilibriumPublished by Elsevier ,2001
- Prevention of a chronic progressive form of experimental autoimmune encephalomyelitis by an antibody against mucosal addressin cell adhesion molecule‐1, given early in the course of disease progressionImmunology & Cell Biology, 2000
- Lymphocyte transendothelial migration toward smooth muscle cells in interleukin-1 ?-stimulated co-cultures is related to fibronectin interactions with ?4?1 and ?5?1 integrinsJournal of Cellular Physiology, 1995
- A Direct Binding Assay for the Vascular Cell Adhesion Molecule-1 (VCAM1) Interaction with α4 IntegrinsCell Adhesion and Communication, 1995
- The pathophysiologic role of alpha 4 integrins in vivo.Journal of Clinical Investigation, 1994
- Activation-dependent recognition by hematopoietic cells of the LDV sequence in the V region of fibronectin.The Journal of cell biology, 1992
- Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytesCell, 1989
- Identification and characterization of the T lymphocyte adhesion receptor for an alternative cell attachment domain (CS-1) in plasma fibronectin.The Journal of cell biology, 1989